Joseph S. Zakrzewski - Jun 22, 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role
Director
Signature
/s/ Andrew Gengos, Attorney-in-Fact
Stock symbol
CYT
Transactions as of
Jun 22, 2021
Transactions value $
$0
Form type
4
Date filed
6/24/2021, 08:54 PM
Previous filing
Jun 17, 2021
Next filing
Nov 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Conversion of derivative security +58.7K 58.7K Jun 22, 2021 See Footnote F1, F2
holding CYT Common Stock 149K Jun 22, 2021 See Footnote F3, F4
holding CYT Common Stock 77.3K Jun 22, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Series B Convertible Preferred Stock Conversion of derivative security -200K -100% 0 Jun 22, 2021 Common Stock 58.7K See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.
F2 Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.
F3 115,208 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest.
F4 Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.